Knight Therapeutics (GUD) Stock Rating Reaffirmed by Raymond James

Knight Therapeutics (TSE:GUD)‘s stock had its “outperform” rating reiterated by stock analysts at Raymond James in a report issued on Friday, BayStreet.CA reports. They currently have a C$10.25 target price on the stock. Raymond James’ target price indicates a potential upside of 38.33% from the stock’s current price.

Knight Therapeutics stock opened at C$7.41 on Friday. The stock has a market cap of $1.06 billion and a P/E ratio of 44.11. Knight Therapeutics has a 52 week low of C$7.27 and a 52 week high of C$8.81.

Knight Therapeutics (TSE:GUD) last announced its earnings results on Thursday, March 14th. The company reported C$0.04 earnings per share for the quarter, beating the consensus estimate of C$0.03 by C$0.01. The firm had revenue of C$3.89 million during the quarter, compared to analyst estimates of C$2.55 million. As a group, analysts expect that Knight Therapeutics will post 0.179999990190736 earnings per share for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Featured Story: QQQ ETF

Analyst Recommendations for Knight Therapeutics (TSE:GUD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.